Docoh
Loading...

ACCD Accolade

News

Pro users get this 30m faster
Analyst Ratings For Accolade
11 Oct 21
Analyst Ratings
Analysts have provided the following ratings for Accolade (NASDAQ:ACCD) within the last quarter:
Morgan Stanley Maintains Overweight on Accolade, Lowers Price Target to $56
11 Oct 21
News, Price Target, Analyst Ratings
Morgan Stanley maintains Accolade (NASDAQ:ACCD) with a Overweight and lowers the price target from $68 to $56.
Expert Ratings For Accolade
8 Oct 21
Analyst Ratings
Within the last quarter, Accolade (NASDAQ:ACCD) has observed the following analyst ratings:
10 Biggest Price Target Changes For Friday
8 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Barclays cut the price target on Constellation Brands, Inc. (NYSE: STZ) from $260 to $257. Constellation Brands shares fell 0.3% to $215.85 in pre-market trading.
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 Oct 21
Pre-Market Outlook, Markets, Movers
Credit Suisse Maintains Outperform on Accolade, Lowers Price Target to $62
8 Oct 21
News, Price Target, Analyst Ratings
Credit Suisse analyst Jailendra Singh maintains Accolade (NASDAQ:ACCD) with a Outperform and lowers the price target from $63 to $62.
Needham Maintains Buy on Accolade, Lowers Price Target to $56
8 Oct 21
News, Price Target, Analyst Ratings
Needham analyst Ryan MacDonald maintains Accolade (NASDAQ:ACCD) with a Buy and lowers the price target from $68 to $56.
SVB Leerink Maintains Outperform on Accolade, Lowers Price Target to $52
8 Oct 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Stephanie Davis maintains Accolade (NASDAQ:ACCD) with a Outperform and lowers the price target from $58 to $52.
Accolade Q2 EPS $(0.97) Misses $(0.56) Estimate, Sales $73.30M Beat $70.46M Estimate
7 Oct 21
Earnings, News
Accolade (NASDAQ:ACCD) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.56) by 73.21 percent. This is a 106.38 percent decrease over losses of $(0.47) per share from the
How Bad Are Accolade's Earnings? | Return On Invested Capital
7 Oct 21
Earnings
Benzinga Pro data, Accolade (NASDAQ:ACCD) reported Q1 sales of $59.53 million. Earnings fell to a loss of $48.02 million, resulting in a 908.93% decrease from last quarter.
Earnings Scheduled For October 7, 2021
7 Oct 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Lamb Weston Hldgs (NYSE:LW) is estimated to report quarterly earnings at $0.39 per share on revenue of $993.09 million.
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Berenberg Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $61
30 Sep 21
News, Price Target, Initiation, Analyst Ratings
Berenberg initiates coverage on Accolade (NASDAQ:ACCD) with a Buy rating and announces Price Target of $61.
Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021
17 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
10 Biggest Price Target Changes For Friday
17 Sep 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
UBS cut FedEx Corporation (NYSE: FDX) price target from $397 to $380. FedEx shares fell 0.2% to $258.00 in pre-market trading.
Baird Upgrades Accolade to Outperform, Lowers Price Target to $54
17 Sep 21
News, Upgrades, Price Target, Analyst Ratings
Baird analyst Vikram Kesavabhotla upgrades Accolade (NASDAQ:ACCD) from Neutral to Outperform and lowers the price target from $58 to $54.
Looking into Accolade's Return on Capital Employed
29 Jul 21
Earnings
After pulling data from Benzinga Pro it seems like during Q1, Accolade (NASDAQ:ACCD) brought in sales totaling $59.53 million. However, earnings decreased 908.93%, resulting in a loss of $48.02 million.
Return on Capital Employed Overview: Accolade
22 Jul 21
Earnings
After pulling data from Benzinga Pro it seems like during Q1, Accolade (NASDAQ:ACCD) brought in sales totaling $59.53 million. However, earnings decreased 908.93%, resulting in a loss of $48.02 million.
Unusual Options Activity Insight: Accolade
19 Jul 21
Options, Markets
Shares of Accolade (NASDAQ:ACCD) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $46.21.

Press releases

Pro users get this 30m faster
Accolade to Showcase Personalized Healthcare for Employers and Health Plans at HLTH Boston 2021
14 Oct 21
Press Releases
SEATTLE, Oct. 14, 2021 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), a healthcare provider that serves over 400 employers and millions of members, will be at HLTH Boston 2021 to engage in discussions about how companies
Accolade Brings WellRight's Corporate Wellness Programs into its partner ecosystem
12 Oct 21
Press Releases
SEATTLE, Oct. 12, 2021 /PRNewswire/ -- Accolade (NASDAQ:ACCD), a healthcare provider serving millions of people and their families, announced today that WellRight, the provider of the nation's most holistic and
Accolade Announces Results for Fiscal Second Quarter 2022
7 Oct 21
Earnings, Press Releases
Fiscal second quarter 2022 revenue of $73.3 million, a 99% increase compared to fiscal second quarter 2021 revenue of $36.8 million Introduced Personalized Healthcare category, focused on human relationships and
Accolade introduces new healthcare category: Personalized Healthcare
21 Sep 21
Press Releases
SEATTLE, Sept. 21, 2021 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with exceptional healthcare, today introduced Personalized Healthcare, a new category
Accolade Invites Media, Investors and General Public to Opening of Evolve21
20 Sep 21
Press Releases
SEATTLE, Sept. 20, 2021 /PRNewswire/ -- WHAT: Accolade, Inc. (NASDAQ:ACCD) the company that provides millions of people and their families with exceptional healthcare will be making an
Accolade to Participate in Upcoming Investor Conferences
7 Sep 21
News, Press Releases
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD), the company reinventing healthcare by helping people live their healthiest lives, will participate in the following upcoming investor
Accolade Welcomes Carrot Fertility to the Trusted Supplier Program
22 Jul 21
Press Releases
SEATTLE, July 22, 2021 /PRNewswire/ -- Accolade announced today that Carrot Fertility has joined its partner ecosystem as part of the company's Trusted Supplier Program (TSP). Carrot, the leading global fertility